Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid

OBJECTIVE: Oligomeric forms of amyloid β protein (oAβ) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti‐Aβ antibodies are capable of lowering oAβ levels in humans. METHODS: We developed an ultrasensitive immunoassay and used it...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Neurol
Main Authors: Yang, Ting, Dang, Yifan, Ostaszewski, Beth, Mengel, David, Steffen, Verena, Rabe, Christina, Bittner, Tobias, Walsh, Dominic M., Selkoe, Dennis J.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Research Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771589/
https://ncbi.nlm.nih.gov/pubmed/31168802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25513
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki